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management protocolsIhab Saad Othman, MD, FRCS ⇑AbstractMany advances in the field of management of retinoblastoma emerged in the past few years. Patterns of presentation of retino-
blastoma in the Middle East region differ from Western community. The use of enucleation as a radical method of eradicating
advanced disease is not easily accepted by patient’s family. We still do see stage E, failed or resistant retinoblastoma and
advanced extraocular disease ensues as a result of delayed enucleation decision. In this review, we discuss updates in management
of retinoblastoma with its implication on patients in our part of the world. Identifying clinical and high risk characteristics is impor-
tant prognostically and are discussed for further management of retinoblastoma cases.
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Retinoblastoma is the commonest primary ocular malig-
nancy of childhood originating from primitive retinoblasts
with tendency towards cone differentiation. Retinoblasts
arise from the inner neuroepithelial layers of the embryonic
optic cup.1 The incidence of retinoblastoma ranges from 1/
15,000 to 1/20,000 live births with an annual incidence in chil-
dren younger than 5 years of 10.9/million. Two distinct forms
of retinoblastoma are present namely sporadic and familial
(Table 1). Most presenting cases are unilateral sporadic. Only
33% of cases are bilateral and all (100%) are hereditary while
15% of unilateral cases presenting with unilateral multifocal
tumors are hereditary. Familial cases represent 10% of cases
and 90% of cases are presenting before age 4 years.1,2 In
Egypt, after reviewing 321 new cases of retinoblastoma over
5 years at the National Eye Center and the Eye and Laser
World Center, the estimated number of new retinoblastomaPeer review under responsibility
of Saudi Ophthalmological Society,
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the mean age-adjusted incidence of retinoblastoma was 9.32
cases per million children per year for children aged 0–
5 years.4 Retinoblastoma constituted 4.8% of childhood can-
cer treated over 10 years at the National Cancer Institute in
Sudan and presented in an advanced stage in 16 out of 25 re-
ported cases.5Genetics
To properly understand the role of retinoblastoma gene, it
is important to revisit the normal cell cycle which represents
the different phases of cell proliferation. Most cells of the
body are in a G0 phase which is a quiescent phase where cells
contain active hypophosphorylated form of retinoblastoma
protein. When there is need for cell division, the cells go into
G1 phase which is a presynthetic growth phase 1 where thej Production and hosting by ElsevierAccess this article online: www.saudiophthaljournal.comwww.sciencedirect.com
March 2012; available online 16 March 2012.
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Figure 1. Growth cycle: most cells of the body are in G0 or quiescent
stage. When they start cell division, they pass through G1, S, G2 and M
phases. Retinoblastoma protein (Rb) in its active hypophosphorylated
form acts on the checkpoint from G1 to S phase to ensure flawless DNA
replication.
164 I.S. Othmancells contain active hypophosphorylated form of retinoblas-
toma protein. S phase is a DNA-synthetic phase. G2 phase
is a premitotic growth phase 2. M phase is a mitotic phase
resulting in duplication of the dividing cell.6
Cyclins are regulatory proteins controlling the cell cycle.
Their regulatory function is accomplished by binding and
activating CDKs (cyclin dependent kinases). CDKs control
the important transition points in cell cycle through phos-
phorylation or dephosphorylation of other proteins. Cyclin-
CDK complexes are regulated by the binding of CDK inhibi-
tors which are important in regulating cell cycle check points
from G1 to S phase.6–8 At this checkpoint, the cell ensures a
flawless DNA replication with all errors repaired before pro-
gression to cell division. This checkpoint is guarded by reti-
noblastoma protein in its active hypophosphorylated form
(Fig. 1). Tumor virus transforming proteins (adenovirus EIA,
simian virus 40 (SV40) antigen, large T and human papilloma
virus [HPV-E7]) induce tumors by binding to and inactivating
the active form of Rb protein.9 Some oncoviruses (SV4O,
HPV, adenovirus) are thought to produce cancer by making
proteins that complex and inactivates the suppressor protein
product of the RB gene.10 The Rb protein unable to bind to
E2F transcription factor is functionally deleted with subse-
quent loss of cellular ability to be inhibited by antigrowth sig-
nals (Fig. 2). Additionally, RB primary tumors harbor cells
with expression of stem cell markers namely CD44 and reti-
nal progenitor markers, PROX1 and syntaxin 1A.11 Presence
of these neural stem cells among others could make the tu-
mor more aggressive in behavior or metastases, reactive
after a quiescent dormant period or more resistant to anti-
cancer therapy.12
The ability of the tumor to be invasive may be explained by
the presence of expression of endothelial nitic acid synthases
(eNOS) and specially the inducible nitric acid synthases
(iNOS).13 Degradation of basement membrane by matrix
metalloproteinases (MMPs) is one of the most critical steps
in various stages of tumor progression, including tumor
angiogenesis, tumor growth, and also local invasion and sub-
sequent distant metastasis.14 Adithi et al.15 have demon-
strated higher expressions of EMMPRIN, MMP-2 and MMP-
9, and TIMP-1 and TIMP-2 in invasive RB tumors. Poorly
differentiated tumors showed higher expression of MMP-2
than tumors that were moderately or well-differentiated
tumors. The expression of TIMP-1 and TIMP-2 was higher inTable 1. Main differences between sporadic and familial retinoblastoma.
Sporadic
retinoblastoma
Familial retinoblastoma
Incidence 90% 5–10%
1/100,000 child
Mean age of
presentation
(months)
30 12
Mutation Somatic: the
mutation is only
in retinoblasts
Germline: the mutation is
in normal cells in the body
and in retinoblasts
Laterality Unilateral
unifocal
Bilateral 70%
May be unilateral but
multifocal 30%
Second cancers No higher risk Increased risk
Genetic
transmission
No Yes
Figure 2. Inactivation of Rb protein by hyperphosphorylation results in
uncontrolled cell replication.invasive tumors. With respect to differentiation, there were
higher expressions of TIMP-1 and TIMP-2 in poorly differenti-
ated tumors, as compared to moderately and well-differenti-
ated tumors. Epithelial cell adhesion molecule (EpCAM) is
highly expressed in RB tumors with invasion compared to tu-
mors without invasion.16 EpCAM plays a role in increased cel-
lular proliferation of RB cells and can be considered a
potential target molecule in the therapeutic interventions
for RB management. Protein 53 (p53) controls powerful stress
response as it integrates upstream signals from many types of
DNA damage and inappropriate oncogenic stimulation, all of
which lead to p53 activation and subsequent regulation of
genes involved in cell cycle arrest or apoptosis.17 Proteomics
has contributed significantly in understanding the biology of
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cells. The altered proteins belong to different categories such
as apoptosis, cell proliferation, signal transduction, meta-
bolic, and active transport processes. PRDX6 and CRYAA
could be potential targets in the clinical management of RB.18The retinoblastoma gene: a tumor suppressor
anti-oncogene
Retinoblastoma (RB1) gene is located on the long arm of
chromosome 13 (13q14 band). This gene is inherited as an
autosomal dominant disease; however it is a ‘‘recessive tu-
mor suppressor gene’’ at the cellular level. RB gene sequence
contains 180,388 base pairs. The Rb gene protein product
(928 amino acids) is a DNA-binding protein found in the nu-
cleus of every cell in the body. The DNA-binding protein ex-
ists in an active hypophosphorylated and an inactive
hyperphosphorylated state. Rb protein is involved in control
of the cell cycle (necessary for terminal differentiation). When
active, Rb protein prevents advancement of cells from G1 to
S phase of the cell cycle (Fig. 1). When the cells are stimu-
lated by growth factors, RB protein is inactivated by phos-
phorylation allowing the cells to go from G1 to S phase.7,19
Once in S phase, cells are committed to divide without addi-
tional growth factor stimulation with lack of terminal differen-
tiation meaning cancer development. Absence of RB protein
or loss causes continual cell division into S phase with lack of
terminal differentiation meaning cancer development and
metastasis (Fig. 2). This requires inactivation of both copies
of the RB1 gene.20,21Figure 3. Hereditary or genetic mutation starts in a sperm ‘‘first hit’’ (red
chromosome in the sperm). This results in a zygote with loss of one allele
of RB gene. A second hit (arrow) occurs in a retinoblast resulting in tumor
formation. All cells of the body carry a hemizygote state of RB.Retinoblastoma gene inheritance
The retinoblastoma (RB) gene is inherited as an autosomal
dominant disease. However at the cellular level it is a ‘‘reces-
sive tumor suppressor gene’’. Normal individuals have two
functional copies of the RB gene (RB, RB). Familial cases
are hemizygous for retinoblastoma gene (RB, rb) ‘‘first hit’’
containing one functional and one inactivated gene, in all
cells of the body. A single functional gene prevents malig-
nant transformation. Tumors develop when the ‘‘second
hit’’ is acquired as a somatic event in the developing retinal
cell, thus both normal suppressor genes in a single retinal cell
are lost or inactivated (rb, rb). The absence of the gene prod-
uct in the homozygous state leads to the development of ret-
inoblastoma (rb, rb). In the hereditary form two mutations
occur, in both a prezygotic cell and a postzygotic cell. First
mutation occurs usually in a sperm or an ovum. All somatic
cells are affected by the first hit. Second mutation occurs in
a somatic retinal cells resulting in multifocal unilateral or bilat-
eral disease or both (Fig. 3).1 Second mutation may affect
other cells of the body resulting in pineal tumors, sarcomas,
breast and lung cancers.22 Tumors in cases of familial retino-
blastoma are frequently bilateral multifocal or unilateral mul-
ticentric (15% of cases).
Sporadic somatic retinoblastoma result from the sequen-
tial inactivation of both genes in a single retinal cell in a pa-
tient whose genotype is normal (RB, RB). Both hits are
acquired events (occur in a post-zygotic somatic cell),
explaining the later onset and unilaterality of the disease.
It is important to counsel the family members affected by
retinoblastoma about the probability of other family mem-bers affection by the disease and to emphasize the impor-
tance of early postnatal screening.1 Genetic risk for
affected siblings is presented in Table 2.Diagnosis
Ninety percent of retinoblastoma cases are presenting be-
low the age of 4 years. Restriction fragment length polymor-
phisms performed on chorionic villus sampling or
amniocentesis cultured cells.23 Additionally, during in vitro
fertilization, absence of preimplantation genetic diagnosis
of retinoblastoma gene mutation allowed pregnancies of a
fetus without retinoblastoma.24
Diagnosis at 1 month of age is highly positive in absence
of leucocoria in patients with family history of retinoblastoma
whether a parent or a sibling is affected (Fig. 4A).25
Typically, intraocular retinoblastoma manifests as leucoco-
ria (90%) and strabismus (35%). More advanced disease pre-
sents with buphthalmos, fixed dilated pupil, spontaneous
hyphema, NVG and heterochromia iridis. Flat retinoblastoma
presents in elderly as a pseudohypopyon. When the tumor
outgrows its blood supply and becomes necrotic, it presents
Table 2. Genetic counseling: risk that subsequent child will have
retinoblastoma.
Unilateral retinoblastoma
Affected parent with no affected children 3%
Normal parents, one affected child 3%
One affected parent, one affected child 30%
Bilateral retinoblastoma
One affected parent, no affected child 40%
Normal parents, one affected child 10%
One affected parent, one affected child 50%
166 I.S. Othmanas an orbital cellulitis-like picture. Extraocular retinoblastoma
is still encountered in our part of the world mainly due to de-
lay in diagnosis, delay in treatment and patients refusal of pri-
mary or secondary enucleation as a curative modality.
Proptosis is related to an orbital tumor due to massive extra-
scleral extension or a fungating mass through corneal perfo-
ration. Preauricular and submandibular lymphadenopathy
and systemic metastases involving bones, or bone marrow,
meninges, paranasal sinuses, salivary glands, lymph nodes,
subcutaneous tissue, liver, spleen, pleura, and testes.1 A spe-
cial entity of retinoblastoma is the trilateral retinoblastoma,
where bilateral intraocular disease presents with a pineal
gland tumor and suprasellar/parasellar neuroblastic tumors
and primitive neuroectodermal tumor.26 This is less com-
monly seen in the era of systemic chemotherapy use.27
Another rare entity is the spontaneous regression or arrest
of retinoblastoma which represents a tumor that undergoesFigure 4. Hereditary retinoblastoma diagnosed in the sibling at age 2 weeks
response after laser transpupillary thermotherapy. C: Tumor recurrence. D
controlled at 60 months follow up.spontaneous growth arrest and or involution leaving a
partially calcified scar without any previous treatment. This
tumor behaves genetically as hereditary retinoblastoma and
follow up is warranted as the tumor may transform to actively
growing retinoblastoma. Primary phthisical eyes harbouring
retinoblastoma are often associated with bilateral disease.
Enucleation of primary phthisical eyes is recommended
as residual viable tumor cells with characteristics of poorly
differentiated retinoblastoma was noted in a majority of
cases.28High risk factors associated with retinoblastoma
It is important to identify high risk factors associated with
retinoblastoma recurrence or metastasis. Clinical high risk
factors include extensively necrotic retinoblastoma which is
found to be associated with extraocular extension, optic
nerve invasion, or choroidal invasion.29 Older age, longer
lag period, hyphema, pseudohypopyon, staphyloma, and
orbital cellulitis are other important high risk factors.30 Delay
in enucleation of more than 3 months after diagnosis and the
use of pre-enucleation chemotherapy in group E eyes with
advanced retinoblastoma downstaged pathologic evidence
of extraocular extension, and increased the risk of metastatic
death from reduced surveillance and inappropriate manage-
ment of high-risk disease.31 Elevated intraocular pressure and
buphthalmos are also associated with high risk pathological
features.32OS. Child underwent chemoreduction with focal therapy. B: initial good
: tumor ablation following Ruthenium-106 plaque application. Tumor
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ophthalmic pathologist should comment on several high risk
factors which have significant implications on patient survival.
Pathological high risk factors include: Retinoblastoma with
invasion into the postlaminar optic nerve and/or posterior
uvea which is found to be a high risk for metastasis and
death.33 Retrolaminar optic nerve invasion and massive uveal
invasion (defined as >3 mm in diameter), scleral invasion with
iris neovascularization and neovascular glaucoma are other
high risk factors (Fig. 5).34 In presence of histopathological
high risk factors, postenucleation chemotherapy use was
effective in preventing metastasis.33,35
Systemic cancer
It is now recognized that a child with retinoblastoma has
approximately a 5% chance of developing another malig-
nancy during the first 10 years of follow-up, 18% during the
first 20 years, and goes up to 44% at age 45 years.36,37 The
30-year cumulative incidence is approximately 35% or even
higher for those patients who received radiation therapy
(external beam therapy) compared with an incidence rate of
6% for those patients who avoided radiation. Osteogenic sar-
coma, often involving the femur, is the most common, but
other tumors such as spindle cell sarcoma, chondrosarcoma,
rhabdomyosarcoma, neuroblastoma, glioma, leukemia, seba-Figure 5. High risk factors with retinoblastoma. (A) Gross section showin
Photomicrograph showing scleral invasion (block arrow) with estrascleral invs
showing malignant round blue cells invasion beyond lamina cribrosa (arrow).ceous cell carcinoma, squamous cell carcinoma, and malig-
nant melanoma have also been recognized as well as brain
cancer.37 The mean latency period for the appearance of
the second primary is approximately 13 years. Patients who
survive a second tumor are at risk for a third, fourth, and even
fifth nonocular tumor.38 Carriers of mutant or deleted RB1
who did not receive high-dose radiotherapy have a much
higher lifetime risk of common epithelial cancers, particularly
cancers of the lung, bladder and, probably, breast, than of
sarcomas and other early-onset cancer. Most of the excess
cancer risks in hereditary retinoblastoma survivors may be
preventable by limiting exposures to DNA damaging agents
(radiotherapy, tobacco, and UV light).39 Regarding associa-
tion of chemotherapy with development of second cancer,
Gombos et al.,40 reported in their retrospective study that
there was a high incidence of secondary acute myelogenous
leukemia in retinoblastoma patients after chemotherapy with
topoisomerase II inhibitors (etoposide), where 12 out of 15
cases of their cohort had received topoisomerase II inhibitors.
Diagnosis of retinoblastoma
Diagnosis of retinoblastoma depends on the stage of dis-
ease presentation. Small intraretinal tumors manifest as
innocuous grayish white or translucent lesions in the neuro-
sensory retina. With increase in size, fluid starts to accumulateg massive choroidal invasion (>3 mm) with optic nerve invasion. (B)
ion (asterisk) (H&E. original magnification 100). (C) Optic nerve section
168 I.S. Othmanaround the tumor as exudative retinal detachment and the
tumor acquire an enlarging caliper feeder artery and draining
vein. The tumor shows intra-lesional calcification in 80–90%
of cases. Retinoblastoma tumors can grow towards the vitre-
ous cavity and is known as endophytic tumor, where due to
discohesiveness of the tumor cells, it easily spread in the vit-
reous cavity and anterior chamber. Otherwise, the tumor may
grow towards the RPE into the subretinal space and is known
as exophytic tumor inducing an exudative retinal detachment
and pushing the retina anteriorly in the vitreous cavity. Other
growth patterns include a diffuse flat infiltration pattern
where the retina becomes slightly thickened by presence of
tumor cells without any tumefaction pausing a myriad of clin-
ical dilemma in diagnosis like uveitis or pseudohypopyon.
Less frequently, the presenting feature can be, hyphema, sec-
ondary to iris neovascularization, vitreous hemorrhage, or
signs of orbital cellulitis.1Differential diagnosis
There is a long listing of differential diagnosis of retinoblas-
toma. In an oncology referral practice, 48% of lesions referred
to as retinoblastoma proved to be pseudoretinoblastoma.41
Table 3 shows the most common simulating lesions with their
differentiating points.1Investigations
Once the diagnosis is established, the patient may under-
go ultrasonography showing tumor size and intrinsic calcifica-
tion, Retcam fundus picture, fluorescein angiography (early
vascularity and late hyperfluorescence of the tumor), detailed
fundus drawings, laboratory work, and an audiogram to
check the general status of the patient and effects of sys-
temic chemotherapy when instated. MRI scans is ordered
to delineate the extent of intraocular spread, optic nerve
and scleral/orbital invasion and to exclude pineal gland tu-
mors. It is contraindicated to perform fine needle aspiration
biopsy or open vitrectomy in any suspected retinoblastoma
case as this will result in extraocular tumor dissemination. Re-Table 3. Common disease in the differential diagnosis of retinoblastoma.
Lesion Unilateral Bilateral Age Comm
Retinoblastoma Yes Yes 18 mo Calciu
Toxocariasis Yes No 6–11 yr CT co
Nega
PHPV Yes No At birth Eye t
vesse
Coats’ disease Yes RARE 18 MO-18 YR 21Ys
Exuda
ROP No Yes In infancy, but
Oxygen not
congenital
RX
Retinal dysplasia – Yes Congenital Micro
Incontinentia
Pigmenti
Yes Infancy Bullou
Retinal Vascu
(letha
Norrie’s disease – X Congenital Males
produ
Medulloepithelioma X – 4 yrs ‘‘Dikt
tumopeated CT scans are better avoided in bilateral cases as it ex-
poses the body to a radiation dose.
Staging of retinoblastoma
Several classifications of retinoblastoma have been devel-
oped to assist in prediction of globe salvage. The most pop-
ular grouping is the Reese-Ellsworth classification which
classified eyes according to quantity and location of the tu-
mor(s) and its associated features such as vitreous seeding.
Their goal was to create a method of predicting success of
external beam radiotherapy for retinoblastoma.42 Similarly,
the International Intraocular Retinoblastoma Classification
(IIRC) was created to assess outcomes in standardized proto-
cols of chemotherapy with focal consolidation therapy for ret-
inoblastoma. Those involved in drafting the IIRC reached
scientific consensus at the 2003 International Retinoblastoma
Symposium in Paris (Table 4).43 A new system of classification
for retinoblastoma has recently been introduced by the
American Committee on Cancer (2009) using the TNM sys-
tem to classify the tumor7. This classification system de-
scribes both clinical (c-TNM) and pathological (p-TNM)
classifications and accounts for both intraocular and extraoc-
ular disease. Adopting the TNM classification system would
allow for the proper interpretation of results of future clinical
trials. It is vital that the classification be instituted exactly as
intended, and its use is now mandatory when publishing in
important peer-reviewed journals (Table 5).44
Management of retinoblastoma
Priorities in management of intraocular retinoblastoma are
tumor control. By controlling the tumor, the ophthalmic
oncologist saves human life. Of course, the optimum method
for tumor control is to save the eye and vision. Unfortunately,
with advanced disease, the eye has to be sacrificed by enu-
cleation. This should be carried out with no hesitation in or-
der to save human life.
The therapeutic approach depends on staging of the dis-
ease, laterality, systemic status, metastatic potential, and risk
of second cancer. Treatment is usually prolonged over manyents
m on ultrasound
ntact with puppies
tive ELISA excludes
ypically microphthalmic with inward-drawn ciliary processes, iris Shunt
ls
male, ST quadrant (End 1st decade) leaky telangiectatic RD Vessels.
tive with lipid. Massive exudation.
phthalmia, most 13 trisomy
s skin eruptions, pigmentation
lar abnormalities, dental and CNS abnormalities, X-linked dominant
l in males) 20 retinal detachment
, X-linked recessive, Deafness, mental retardation Norrin (gene
ct)
yoma’’, benign and malignant, Teratoid and nonteratoid. Teratoid
rs, contain cartilage, muscle, brain, most ciliary body
Table 4. International retinoblastoma symposium (Paris, 2003).
Group A
All tumors are 3 mm or smaller, confined to the retina and at least 3 mm from the foveola and 1.5 mm from the optic nerve. No vitreous or
subretinal seeding is allowed
Group B
Eyes with no vitreous or subretinal seeding and discrete retinal tumor of any size or location. Retinal tumors may be of any size or location not in
group A. Small cuff of subretinal fluid extending 65 mm from the base of the tumor is allowed
Group C
Eyes with focal vitreous or subretinal seeding and discrete retinal tumors of any size and location. Any seeding must be local, fine, and limited so as
to be theoretically treatable with a radioactive plaque. Up to one quadrant of subretinal fluid may be present
Group D
Eyes with diffuse vitreous or subretinal seeding and/or massive, nondiscrete endophytic or exophytic disease. Eyes with more extensive seeding
than Group C. Massive and/or diffuse intraocular disseminated disease may consist of ‘greasy’ vitreous seeding or avascular masses. Subretinal
seeding may be plaque-like, includes exophytic disease and >1 quadrant of retinal detachment
Group E
Eyes that have been destroyed anatomically or functionally with one or more of the following: Irreversible neovascular glaucoma, massive
intraocular hemorrhage, aseptic orbital cellulitis, tumor anterior to anterior vitreous face, tumor touching the lens, diffuse infiltrating
retinoblastoma, phthisis or pre-phthisis
Table 5. Definitions of tumor, node and metastasis.
Clinical classification (cTNM)
Primary tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumors no more than 2/3 the volume of the eye with no vitreous or subretinal seeding
 T1a: No tumor in either eye is greater than 3 mm inlargest dimension or located closer than 1.5 mm to the optic nerve or fovea (coinciding with
IIRC Group A)
 T1b: At least one tumor is greater than 3 mm in largest dimension or located closer than 1.5 mm to the optic nerve or fovea. No retinal
detachment or subretinal fluid beyond 5 mm from the base of the tumor (coinciding with IIRC Group B)
 T1c: At least one tumor is greater than 3 mm in largest dimension or located closer than 1.5 mm to the optic nerve or fovea, with retinal
detachment or subretinal fluid beyond 5 mm from the base of the tumor (coinciding with IIRC Group C)
T2 Tumors no more than 2/3 the volume of the eye with vitreous or subretinal seeding
Can have retinal detachment
 T2a: Focal vitreous and/or subretinal seeding of fine aggregates of tumor cells is present, but no large clumps or ‘‘snowballs’’ of tumor cells
(coinciding with IIRC Group C)
 T2b: Massive vitreous and/or subretinal seeding is present, defined as diffuse clumps or ‘‘snowballs’’of tumor cells (coinciding with IIRC Group D)
T3 Severe intraocular disease
 T3a: Tumor fills more than 2/3 of the eye(coinciding with IIRC Group D)
 T3b: One or more complications present, which mayinclude tumor-associated neovascular or angle closure glaucoma, tumor extension into the
anterior segment, hyphema, vitreous hemorrhage, or orbital cellulitis (coinciding with IIRC Group E)
T4 Extraocular disease (detected by imaging studies)
 T4a: Invasion of optic nerve
 T4b: Invasion into the orbit
 T4c: Intracranial extension not past chiasm
 T4d: Intracranial extension past chiasm
Regional lymph nodes (N)
NX: Regional lymph nodes cannot be assessed
N0: No regional lymph node involvement
N1: Regional lymph node involvement (preauricular, cervical, submandibular)
N2: Distant lymph node involvement
Metastasis (M)
M0 No metastasis
M1 Systemic metastasis
 M1a: Single lesion to sites other than CNS
 M1b: Multiple lesions to sites other than CNS
 M1c: Prechiasmatic CNS lesion(s)
 M1d: Postchiasmatic CNS lesion(s)
 M1e: Leptomeningeal and/or CSF involvement
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lifelong follow up. In our area of the world, the socioeconomic
status of the patient has to be considered in decision making
and its ability to commit. If the decision comes to enucleation,
it is important to spend time explaining to the parents the
necessity and the drawbacks of delaying the decision on the
life of the child and to answer every question in the mind of
the parents about cosmetic rehabilitation of the child.Currently available treatment methods for retinoblastoma
include intravenous chemoreduction, diode laser thermo-
therapy, cryotherapy, plaque radiotherapy, external beam
radiotherapy, enucleation, orbital exenteration, and systemic
chemotherapy for metastatic disease.44 Unilateral retinoblas-
toma usually present at a late stage and are generally man-
aged with enucleation if the eye is classified as stage E; for
those eyes in groups A to D, chemoreduction or focal
170 I.S. Othmanmeasures are used. For bilateral retinoblastoma, chemore-
duction is utilized in most cases even if one eye is harboring
an advanced disease. Enucleation decision is delayed till the
end of six cycles and active focal management of the more
advanced eye is usually carried out after the second cycle
of chemotherapy, along with focal treatment of the less ad-
vanced eye.
Chemoreduction
Systemic chemoreduction is given to the patients in order
to reduce tumor volume to allow for therapeutic measures to
be more focused, effective and affecting less of the retinal tis-
sues not harboring tumor anymore.46 Systemic chemother-
apy regimen for chemoreduction of retinoblastoma is not
uniformly agreed upon. One,47,48 two,49 three,50–53 and even
four54 drug regimen have been used with almost similar re-
sults in tumor control and ocular salvage. There is a general
consensus about the use of systemic chemotherapy for six cy-
cles given every 3–4 weeks. Two-drug regimen of systemic
chemotherapy using carboplatin and etoposide were found
to have mild and reversible acute side effects in our study.3
The toxicity of vincristine reported to be in up to 40% of pa-
tients was avoided using this protocol.55 We use systemic
chemotherapy regimen for six cycles given every 3–4 weeks
to allow for adequate tumor reduction. Following two cycles
of systemic chemotherapy, most tumors shrink with a mean
of 35% in tumor base and 50% in thickness with resolution
of subretinal fluid. Focal therapy to the individual tumors is
usually delivered at cycle 2. With such a regimen, tumor con-
trol was achieved in 100% of group A eyes, 93% of group B
eyes, 86% of group C eyes, 48.8% of group D eyes and 0%
for group E eyes. Our results for globe survival matched
the reported literature in developing countries53,56,57 and
approaching results of developed countries.49–52,54,55
After finishing active management, follow up is warranted.
The child is examined under anesthesia monthly to observe
for new tumor development, marginal recurrence or seeds
reactivation following the disappearance of the tumor inhib-
iting effect of chemotherapy. Focal therapy is delivered
according to the situation, and the follow up is kept monthly
as long as active management is performed. Recurrent tu-
mors, new tumors or retinal seeds recur in the first 2 years
after treatment and it is crucial to early detect and properly
manage recurrences.58,59
Focal therapies
Focal therapies include transpupillary diode laser thermo-
therapy (TTT), cryotherapy, and plaque radiotherapy. Com-
monly, focal therapies are applied to an eye while the child
is receiving chemoreduction, and they are repeated to each
tumor at each chemotherapy session. We insist on delivering
focal therapy the same day or the day before chemotherapy
to enhance the synergistic effect of thermotherapy to
chemotherapy.59
The goal is to deliver a temperature of 42–60 C, a tem-
perature that is below the coagulative threshold and thus
sparing the retinal vessels of photocoagulation. The combi-
nation of heat and chemotherapy is termed chemothermo-
therapy. Power settings depend on the tumor thickness
with thinner tumor receiving less power. Usual range of
power settings with diode laser TTT is from 300 to 800 mWapplied to cover the whole tumor surface with a safety mar-
gin around it. Usual set up of the laser machine is 10 min
and the large spot laser indirect ophthalmoscope is applied
over the lesion for sometime and moved slowly to cover
the tumor aiming at seeing a delayed onset grayish white
reaction, thus ensuring significant in-depth tumor penetra-
tion. It is important to spend time treating tumors with subtle
dispersed retinal seeds (Fig. 4B).
Plaque radiotherapy is used as a primary or more com-
monly a secondary treatment modality for tumors that fail
other focal therapies, even those that reach a moderate size,
up to 8 or 10 mm in thickness. We use Ruthenium/Rhodium-
106 applicators which are mainly emitting Beta irradiation
up to a tumor thickness of 6–7 mm after placing the plaque
over the sclera to cover the tumor base with an extra 2–
3 mm of safety margin. Different plaque diameters exist up
to 25 mm wide. The radiation dose to the tumor apex is
around 50 Gy delivered over a period of 2–5 days depending
on plaque activity. Tumor control rate following plaque radio-
therapy as a primary therapy or after failed chemothermo-
therapy is about 90%. Success decreases to 75% if plaque is
used after tumor recurrence following external beam radio-
therapy and mounts to 75% (Fig. 4 D).60
Cryotherapy is applied for peripheral tumors under 3 mm
in greatest dimension. A triple freeze thaw application is used
insisting on seeing the ice ball beyond the apex of the tumor
at each application. It is a critical modality for management of
recurrent subretinal seeds near the ora serrata.
External beam radiotherapy
This modality uses photons delivered from a remote ma-
chine to the eye. EBRT has fallen out of use because of its lo-
cal complications effect and associated high incidence of
second cancers in the irradiated zone years after cure from
the disease in hereditary forms of retinoblastoma. EBRT is
preserved only to bilateral advanced disease with diffuse vit-
reous seeds as a last globe preserving modality in patients
refusing bilateral enucleation after failure of all other conser-
vative treatment modalities. We should specify to radiologist
to give a ‘‘whole eye technique’’ to cover the diffuse vitreous
seeds when radiotherapy is required. A ‘‘lens sparing tech-
nique’’ might give adequate control if combined with focal
therapy to cover the peripheral tumors at the ora serrata.61
External beam radiotherapy may induce a second cancer in
the field of irradiation, and this was the driving force behind
the use of systemic chemotherapy for chemoreduction that is
largely replaced external beam radiotherapy.36–38,62
Subconjunctival chemoreduction for retinoblastoma
Increasing interest has emerged in delivering chemother-
apy locally to the eye while minimizing systemic exposure.
Chemotherapy has been given as posterior subtenon carbo-
platin injection (20 mg/2 cc)63 or carboplatin given as a nano-
molecule.64 Periocular topotecan is injected in a fibrin
sealant65 or as an episcleral implant.66 Other delivery systems
included depot gels,solid polymers, miniature catheters
placed adjacent to the sclera and iontophoresis systems.67
Local side effects include inflammation, ptosis, scarring and
loss of sight.67
Posterior subtenon periocular boost of subconjunctival
chemotherapy is given in advanced retinoblastoma in both
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chemoreduction.Selective intraophthlamic artery melfalan injection
Japanese investigators have been using an interventional
radiology technique of infusing melfalan into the carotid ar-
tery for retinoblastoma since 1988. Their technique used a
balloon catheter inserted into a femoral artery puncture
and a (balloon) catheter that was passed into the internal car-
otid artery and inflated to occlude the internal carotid artery
(for as long as 30 min) beyond the orifice of the ophthalmic
artery, allowing chemotherapy infused into the cervical inter-
nal carotid artery to perfuse the eye selectively without per-
fusing the brain. In 1452 procedures of 1469 trials, the eye
preservation rate was 100% in group A, 88% in group B,
65% in group C, 45% in group D, and 30% in group E accord-
ing to the International Classification of Intraocular Retino-
blastoma. Two eyes (0.5%) developed severe orbital
inflammation, and 2 eyes (0.5%) had diffuse chorioretinal
atrophy. Transient periocular swelling or redness occurred
in some cases. No severe systemic adverse events were de-
tected. Transient bronchospasm occurred in 1 patient
(0.3%), and transient vomiting occurred in several patients.68
In 2008, Abramson et al., reported preliminary results of a
modified technique by directly injecting melfalan into the
ophthalmic artery using a microcatheter. The goal was to
achieve a targeted focal delivery of chemotherapy to the tu-
mor with minimal systemic complications and possibly more
efficacy. Since then, the technique has been adopted in many
centers worldwide.69–71
Superselective ophthalmic artery infusion of chemother-
apy was used initially as an ocular salvage therapy in ad-
vanced group V retinoblastoma as a primary and secondary
treatment modality. With more comfort of the technique,
cannulation of one or both ophthalmic arteries with chemo-
therapy injection could be done via femoral artery cannula-
tion and is used in less advanced disease stage as a
primary or secondary treatment modality. This technique
seems to control advanced disease, subretinal seeds and vit-
reous seeds whether primary or recurrent (Fig. 6).72,73
A recent report showed that the globe salvage rate in
group E in eyes managed with intra-arterial chemotherapyFigure 6. (A) Vitreous seeds and inferonasal tumor recurrence following c
retinoblastoma. (B) Tumor and vitreous seeds control following 3 monthly injewas 30%. Three injections at monthly intervals were given
and subretinal and vitreous seeds recurrence was noted at
one year follow up necessitating enucleation.74
The minimum age with successful cannulation was
3 months and the main drug used is melfalan, at a dose of
(0.35 mg/kg) or 5–7.5 mg/injection. Other additional drugs
include topotecan and carboplatin depending on the stage
of the disease and tumor response.69
Reported complications include transient eyelid edema,
blepharoptosis, cilia loss, and orbital congestion with tempo-
rary dysmotility. Vascular events are of concern and include
ophthalmic artery stenosis (permanent or temporary). Con-
comitant central or branch retinal artery occlusion (perma-
nent or temporary). Retinal pigment epithelial mottling with
development of later-onset underlying choroidal atrophy.
Sectoral choroidal occlusive vasculopathy leading to chorio-
retinal atrophy was also observed (Fig. 7). There was no evi-
dence of metastasis, stroke, brain injury, or persistent
systemic toxic effects.75,76
In a study of enucleated globes following intraarterial
melfalan, showed a range of tumor response from complete
regression to no regression with viable tumor. Ischemic atro-
phy involving the outer retina and choroid was noted, with
foreign intravascular foreign material resembling granuloma-
tous reaction observed within occluded vessels.77
Selective ophthalmic artery melfalan injection is a promis-
ing new technique. We have been using this technique to
treat 20 patients with advanced stage D/E disease in addition
to focal therapy (Othman et al., unpublished data). Two of the
patients experienced ophthalmic artery occlusion (Fig. 7). Ele-
ven of 15 cases of stage E disease and 2 out of 5 cases of stage
D ended up by enucleation. All cases were combined by focal
therapy. It is our recommendation to cautiously use this tech-
nique for advanced disease as a last resort of therapy when
the patient’s family is refusing enucleation as a primary and/
or secondary ocular salvage procedure.Enucleation
Enucleation is an important tool in management of retino-
blastoma. It is indicated in advanced unilateral disease, stage
E retinoblastoma, after failure of tumor control by other
modalities, or in eyes with secondary glaucoma, vitreoushemofocal therapy and external beam radiation for unilateral sporadic
ction of intraophhtlamic artery melfalan.
Figure 7. Ophthalmic artery occlusion with severe choroidal RPE mot-
tling following a second injection of ophthlamic artery melfalan.
172 I.S. Othmanhemorrhage, hyphema, pseudohypopyon. Enucleation is
associated with placement of an orbital implant of adequate
size made of porous implants (hydroxyapatite, porous poly-
ethylene, or aluminium oxide) or non-porous implants like
polymethylmethacrylate sphere and silicone, wrapped in do-
nor sclera, or synthetic viryl mesh or directly placed in the or-
bit with attachment of the 4 recti muscles around it using 6/0
Vicryl sutures.78 Closure of conjunctiva should be in layers
starting by the tenon’s capsule then the conjunctival layer.
The superior rectus muscle should not be tightened to the
muscle complex to avoid induced ptosis by pulling on the
rectus/levator complex and adding to the superior margin
of the prosthesis, to restore functional length and create a
more anatomic pivot point for the levator muscle.79 It is
important to check the integrity of the fornices and to put
a conformer at the end of surgery. Handling the globe should
be done according to the following guidelines.Table 6. Pathologic classification (pTNM).
Primary tumor (pT)
pTX Primary tumor cannot be assessed
pT0 No evidence of primary tumor
pT1 Tumor confined to eye with no optic nerve or choroidal invasion
pT2 Tumor with minimal optic nerve and/or choroidal invasion:
 pT2a: Tumor superficially invades optic nerve head but does not extend
 pT2b: Tumor superficially invades optic nerve head butdoes not extend
pT3 Tumor with significant optic nerve and/or choroidal invasion:
 pT3a: Tumor invades optic nerve past lamina cribrosa but not to surgica
 pT3b: Tumor invades optic nerve past lamina cribrosa but not to surgica
pT4 Tumor invades optic nerve to resection line or exhibits extraocular ext
elsewhere
 pT4a: Tumor invades optic nerve to resection line but no extraocular ext
 pT4b: Tumor invades optic nerve to resection line and extraocular exten
Regional Lymph Nodes (pN)
pNX Regional lymph nodes cannot be assessed
pN0 No regional lymph node involvement
pN1 Regional lymph node involvement (preauricular, cervical)
pN2 Distant lymph node involvement
Metastasis (pM)
cM0 No metastasis
pM1 Metastasis to sites other than CNS
 pM1a Single lesion
 pM1b Multiple lesions
 pM1c CNS metastasis
 pM1d Discrete mass(es) without leptomeningeal and/or CSF involvement
 pM1e Leptomeningeal and/or CSF involvementAdvanced stage E unilateral disease is managed by enu-
cleation as it is more likely to have elevated intraocular pres-
sure, invasion of the anterior chamber, uveal tract, optic
nerve and sclera on histopathological examination.80
In unilateral retinoblastoma, about 70% of cases are man-
aged by enucleation due to late presentation. Our philosophy
in management of bilateral cases was to initiate systemic
chemoreduction using carboplatin and etoposide for six cy-
cles, start to manage both eyes with focal therapy mainly from
the second chemotherapy cycle, delaying the decision for
enucleation of the advanced eye till the end of chemotherapy
to assess the response and to perform enucleation when indi-
cated using the largest possible orbital implant in a more suit-
able environment for surgery. This practice might be
associated with less orbital volume growth retardation
through delaying enucleation beyond the first year of life.81,82
We agree with others regarding the importance of ade-
quate orbital volume replacement in pediatric population
to obviate the need of further surgeries in adulthood.82 As
a rule of thumb, we use an 18 mm diameter orbital implant
before 1 year of age and a 20 mm orbital implant after 1 year
of age in orbital volume replacement. An 18 mm implant has
a volume of 3.1 ml and a 20 mm implant replaces an orbital
volume of 4.2 ml.83 An enucleated globe has a volume of
5.5–9 ml depending on age and globe size.84 Both silicone
implant and hydroxyapatite implants are used in our practice.
There was no tumor progression under chemotherapy in our
series even in eyes with advanced disease. A recent report
indicated significant orbital growth retardation after enucle-
ation, even with a hydroxyapatite implant. Orbital growth
retardation was correlated with operation age and also more
prominent in children treated in the first year of life.82
Pathologic staging
If an eye is enucleated, pathology could provide histologic
verification of the disease and pathologic staging couldpast lamina cribrosa or tumor exhibits focal choroidal invasion
past lamina cribrosa and exhibits focal choroidal invasion
l resection line or tumor exhibits massive choroidal invasion
l resection line and exhibits massive choroidal invasion
ension
ension identified
sion identified
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Both clinical and pathologic data may be used to plan the
management of a case. The International Retinoblastoma
Staging Working Group (IRSWG) uniformed definitions of
the pathological entities: massive choroidal invasion stated
as a maximum diameter (thickness or width) of invasive tumor
focus of 3 mm or more that may reach the scleral tissue. Focal
choroidal invasion is defined as a tumor focus of less than
3 mm (thickness or width) and not reaching the sclera. Optic
nerve invasion is classified as prelaminar, laminar, retrolami-
nar, or tumor at surgical margin, and the measurement of
the depth of invasion should also be recorded.Handling of the enucleated globe
When fresh tumor is required, it is important that the enu-
cleated globe be moved to a sterile area in the operating
room away from the operative field due to the risk of contam-
inating the operating field with the harvested tumor cells.
After collecting the specimen, the surgeon should change
his/her gloves before re-entering the operative field. The op-
tic nerve should be measured for length and the cut margin
should be obtained before opening the eye. The first tech-
nique proposed is the opening of a window in the sclera at
the edge of the area containing most of the tumor. The win-
dow may be obtained using a corneal trephine or by using a
sharp blade. Fresh tumor then should be retrieved from areas
without necrosis. After tumor harvesting, the eye is then
placed in sufficient formalin to cover the globe and fixed for
at least 48 h.
Consensus was reached as to the examination of the entire
eye microscopically by submitting a total of four blocks. One
block is the central pupil–optic nerve (PO) section containing
the optic nerve, tumor, and anterior chamber structures. Two
blocks will contain the calottes (remainder of ocular tissue
after obtaining the PO) in anterior–posterior segments
embedded on edge to examine more choroidal surface. The
fourth block contains the cross section of the margin of the
optic nerve, obtained before opening the eye. The slides of
the PO section should contain the optic nerve head, lamina
cribrosa, and postlaminar optic nerve in a single plane of
section.85
Table 6 demonstrates histopathologic classification of
enucleated globes.References
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